GlassScriptPhysician profile
Amber L Mcgee
NPI 1326334962
$1,277.53
in general payments reported to CMS, 2019-2025
21 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.14 · 2022: $40.21 · 2023: $109 · 2024: $716 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176 · Education: $20.22 · Travel and Lodging: $17.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.17 |
| Education | $20.22 |
| Travel and Lodging | $17.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $340.43 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.77 | 2023-2024 | |
| Recor Medical INC | $120.73 | 2024 | Paradise Renal Denervation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.95 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $71.92 | 2024-2025 | Rivfloza, Ozempic |
| Amgen INC. | $52.77 | 2024 | Tavneos |
| Akebia Therapeutics INC | $49.06 | 2024-2025 | Vafseo |
| Novartis Pharmaceuticals Corporation | $48.95 | 2025 | |
| Vifor Pharma, INC. | $48.59 | 2024-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $47.91 | 2024 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $45.85 | 2023-2024 | Farxiga, Lokelma |
| Ani Pharmaceuticals, INC. | $31.76 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $28.17 | 2025 | Acthar |
| Neurocrine Biosciences, INC. | $28.00 | 2022 | |
| Daiichi Sankyo INC. | $26.02 | 2025 | Injectafer |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $23.14 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.45 | 2025 | Livtencity |
| Calliditas Therapeutics US INC. | $20.70 | 2025 | Tarpeyo |
| Genzyme Corporation | $19.10 | 2025 | |
| Chiesi USA, INC. | $18.05 | 2025 | Elfabrio |
| Urovant Sciences INC | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.